OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
종목 코드 OPK
회사 이름OPKO Health Inc
상장일Nov 02, 1995
CEOCruz (Tony F)
직원 수2997
유형Ordinary Share
회계 연도 종료Nov 02
주소- -
도시- -
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가- -
우편 번호- -
전화- -
웹사이트- -
종목 코드 OPK
상장일Nov 02, 1995
CEOCruz (Tony F)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음